Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Interactive Tools
Learning Modules
Presentations
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
home
Articles
HER2+ MBC Adverse-Event Management
July 14th 2020
After Progression on PIK3CAi Therapy: MTOR Inhibition
July 14th 2020
Significance of PIK3CA Mutation in HR+ Breast Cancer
July 14th 2020
Mechanisms of Resistance to CDK4/6 Inhibitors
July 14th 2020
CDK4/6 Meta-Analysis Data
July 14th 2020
CDK4/6 Clinical Trial Survival Data Impact
July 14th 2020
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer
July 14th 2020
Next-Generation Sequencing: Triple Negative Breast Cancer
July 14th 2020
Phase 3 ASCENT Regimen Accelerated Approval
July 14th 2020
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews
July 14th 2020
ASCO New Data: PARP Inhibitors
July 14th 2020
KEYNOTE-355 Regimen’s Role in Treatment Paradigm
July 14th 2020
PD-L1 Testing Standard of Practice
July 14th 2020
Phase 3 KEYNOTE-355 Overview
July 14th 2020
Perspectives on Recent Progress: Program Overview
July 14th 2020
Educational Tools for Possible Drug-Induced ILD
June 30th 2020
Management of Patients Who Develop ILD
June 30th 2020
Changes in Treatment Goals due to Drug Induced ILD
June 30th 2020
Risk of ILD as a Class Effect and Identifying ILD
June 30th 2020
Risks for Developing ILD in Gastrointestinal Cancer Studies
June 30th 2020
NEXT PAGE
<
1
2
3
>
PREVIOUS PAGE